Navigation Links
Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
Date:8/17/2012

DALLAS and NEW YORK, Aug. 17, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

The investor conference call is scheduled to be held on Thursday, August 23, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. 

A replay of the call will be available starting on August 23, 2012 at 1:00 pm ET, through September 6, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company and Media

Contact: Investor RelationsChristine Berni

Donald C. WeinbergerDirector of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
2. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
3. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
4. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
5. Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference
6. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
7. Nouveau Life Offers Potential Distributors Online Access to Company and Contract
8. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
9. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
10. United Spinal Appointed to U.S. Access Board: Developing Accessible Standards for Medical Diagnostic Equipment
11. European Markets for Vascular Access Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... According to a new ... by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical ... User - Global Forecast to 2021", published by ... 2016 to 2021. This market is expected to ... 715.4 Million in 2016, at a CAGR of ...
(Date:1/13/2017)... January 13, 2017 The 2016 election ... with several states voting in favor of legalizing cannabis for ... Cannabis market in the U.S. In addition, the state of ... in annual cannabis products sales. The ArcView Group has published ... the legal cannabis sales in the U.S. last year reached $6.7 ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... today announced the addition of Victor Giamos, MD to their medical staff, ... and Managing Partner at North Shore Eye Care, a division of SightMD. Dr. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide ... wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue their ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. ... the official journal of The American Society for Aesthetic Plastic Surgery, in which ... is designed to correct drooping, retracted lower eyelids, which usually result from genetics, ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... latest in 3-D scanning device which is capable of taking digital impressions of teeth ... dentistry, such as CAD CAM restorations , in terms of speed, efficiency and ...
(Date:1/15/2017)... ... ... In this role, Courtney will be responsible for developing new business initiatives ... mark. This certification program was created by ASL and the nonprofit Asthma and Allergy ... for the 60+ million people living in the U.S. with asthma and allergies. Courtney ...
Breaking Medicine News(10 mins):